Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-cell receptor peptide therapy in EAE and MS

A A Vandenbark1, D N Bourdette, R Whitham

  • 1V.A. Medical Center, Portland, OR 97201.

Clinical and Experimental Rheumatology
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.

Journal of neuroimmunology·2021
Same author

Antigen-stimulated rosette formation by T lymphocytes in experimental allergic encephalomyelitis.

Neurochemical research·2013
Same author

Correlation between active rosette formation and delayed cutaneous hypersensitivity in experimental allergic encephalomyelitis.

Neurochemical research·2013
Same author

Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease.

Mucosal immunology·2010
Same author

NMDA receptor encephalitis mimicking seronegative neuromyelitis optica.

Neurology·2010
Same author

Clinical trial of a formal group fatigue program in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2010
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Synthetic T-cell receptor (TCR) peptides targeting specific V beta genes show promise for treating autoimmune diseases like multiple sclerosis (MS). These TCR peptides effectively modulated T-cells in MS patients without adverse effects, suggesting a potential new therapeutic avenue.

Area of Science:

  • Immunology
  • Neuroimmunology
  • Autoimmune Diseases

Background:

  • T-cell receptor (TCR) V beta gene expression is implicated in autoimmune encephalomyelitis (EAE) in Lewis rats.
  • Specific V beta gene sequences, such as V beta 8.2, are overexpressed in encephalitogenic T cells and effective in EAE prevention and treatment.
  • Identifying disease-relevant V beta genes is crucial for developing targeted immunotherapies.

Purpose of the Study:

  • To evaluate optimal conditions for identifying disease-relevant T-cell receptor (TCR) V beta genes.
  • To investigate the expression patterns of V beta genes in the central nervous system (CNS) and cerebrospinal fluid (CSF).
  • To assess the therapeutic potential of synthetic TCR V beta peptides in multiple sclerosis (MS) patients.

Main Methods:

Related Experiment Videos

  • Analysis of TCR V beta gene expression in activated, IL-2 responsive T cells from Lewis rats with EAE.
  • Evaluation of basic protein-reactive T cells from MS patients for V beta gene expression bias.
  • Treatment of MS patients with synthetic TCR V beta 5.2 and V beta 6.1 CDR2 peptides and assessment of anti-TCR T cell frequency and immune response.

    • Main Results:

    • V beta 8.2 gene expression was most pronounced in the CNS of rats with EAE, with weaker expression in the CSF.
    • MS patients showed biased expression of V beta 5.2 and V beta 6.1 in basic protein-reactive T cells.
    • Treatment with synthetic TCR V beta 5.2 and V beta 6.1 peptides increased anti-TCR reactive T cells in most MS patients, without side effects or compromising recall immunity.

    Conclusions:

    • Synthetic TCR V beta peptides can modulate T-cell responses in human autoimmune diseases.
    • Identifying disease-relevant V beta genes is a critical step for the successful application of TCR peptide therapy.
    • TCR peptide therapy holds potential for treating human autoimmune diseases, including multiple sclerosis.